Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONTRAFECT CorpCFRX · Entity 116797 | Director | May 17, 2022 | May 18, 2022 |
| SERA PROGNOSTICS, INC.SERA · Entity 304 | Director | July 10, 2026 | July 14, 2026 |
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director | August 12, 2019 | August 14, 2019 |
| Viracta Therapeutics, Inc.VIRX · Entity 85616 | Director | June 20, 2024 | June 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONTRAFECT Corp
Report date May 17, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2032-05-17 | Direct | 42,000 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 42,000 · Balance 42,000 F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date.
SERA PROGNOSTICS, INC.
Report date July 10, 2026 · Filed July 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 47,088 |
Ending reported balance
After 2026-07-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-10 · Grant · Acquired 22,426 · Balance 45,139 F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Row 2 · 2026-07-10 · Grant · Acquired 1,949 · Balance 47,088 F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10 | Direct | 34,494 |
Reported balance
After 2026-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-10 · Grant · Acquired 34,494 · Balance 34,494 F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10 | Direct | 2,998 |
Reported balance
After 2026-07-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-10 · Grant · Acquired 2,998 · Balance 2,998 F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
TherapeuticsMD, Inc.
Report date August 12, 2019 · Filed August 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,144 |
Reported balance
After 2019-08-12 transaction · row 1
1 source rowRow 1 · 2019-08-12 · Purchase · Acquired 3,144 · Balance 3,144 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.17 to 3.18, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.17 to 3.18, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4.
Viracta Therapeutics, Inc.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2034-06-20 | Direct | 50,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 50,000 · Balance 50,000 F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MOMENTA PHARMACEUTICALS INC
Report date October 01, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.71 · Expires 2029-12-11 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.09 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 14, 2026 22:41 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 2,998 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001736026-26-000002 · ownership.xml · derivative · entry 4 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,998 Underlying: Class A Common Stock · 2,998 shares Expires 2036-07-10 F4 · derivative.exercise_date: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 22:41 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 34,494 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001736026-26-000002 · ownership.xml · derivative · entry 3 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,494 Underlying: Class A Common Stock · 34,494 shares Expires 2036-07-10 F3 · derivative.exercise_date: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 22:41 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 1,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001736026-26-000002 · ownership.xml · nonDerivative · entry 2 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,088 F2 · shares: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 22:41 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 22,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001736026-26-000002 · ownership.xml · nonDerivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,139 F1 · shares: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 22:37 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0000950170-25-083332 · ownership.xml · derivative · entry 2 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2035-06-05 F2 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 5, 2025. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 22:37 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 15,596 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083332 · ownership.xml · nonDerivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,713 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 5, 2025, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 19:43 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000950170-24-076994 · ownership.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:31 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 10,549 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001534969-24-000131 · wk-form4_1717792288.xml · derivative · entry 2 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,549 Underlying: Class A Common Stock · 10,549 shares Expires 2034-06-06 F2 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 6, 2024, subject to the reporting person continuing to provide services to the issuer. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:31 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 7,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001534969-24-000131 · wk-form4_1717792288.xml · nonDerivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,117 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 6, 2024, subject to the reporting person continuing to provide services to the issuer. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 18:11 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001209191-23-036000 · doc4.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| June 08, 2023 Filed Jul 7, 2023 20:23 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 63,265 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001534969-23-000079 · wk-form4_1688761417.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,265 Underlying: Class A Common Stock · 63,265 shares Expires 2033-06-08 F1 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 8, 2023. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:51 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001209191-22-035950 · doc4.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:12 UTC | CONTRAFECT Corp CFRX · Entity 116797 | GrantOptions (Right to Buy) · Derivative | 42,000 | $3.35 Strike: $3.35 | $140,700.00 |
DisclosureSEC source: 0001209191-22-030285 · doc4.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date. Read SEC document |
| April 11, 2022 Filed Apr 12, 2022 21:22 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 140,823 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001534969-22-000050 · wf-form4_164979854182714.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,823 Underlying: Class A Common Stock · 140,823 shares Expires 2032-04-11 F1 · derivative.exercise_date: These stock options vest over three years as follows: 1/36 of the original grant amount vests in monthly installments for three years following the vesting commencement date, which is April 11, 2022. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 18:10 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $9.19 | $0.00 |
DisclosureSEC source: 0001209191-21-052009 · doc4.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-08-16 F1 · derivative.exercise_date: One thirty-sixth (1/36) of the shares subject to the option shall vest monthly beginning on the one month anniversary of August 16, 2021 (the "Vesting Commencement Date"), subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 20:34 UTC | CONTRAFECT Corp CFRX · Entity 116797 | GrantOPTIONS (RIGHT TO BUY) · Derivative | 16,000 | $0.00 Strike: $5.89 | $0.00 |
DisclosureSEC source: 0000899243-21-006062 · doc4.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: COMMON STOCK · 16,000 shares Expires 2031-02-07 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the date of grant and the remaining 75% of the total shares vest in equal annual installments on the first three anniversaries of the date of grant, subject to continued service with the issuer through each vesting date. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:08 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $38.09 | Not disclosed |
DisclosureSEC source: 0001179110-20-010058 · edgar.xml · derivative · entry 2 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-06-23 F1 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. F1 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:08 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $15.71 | Not disclosed |
DisclosureSEC source: 0001179110-20-010058 · edgar.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-12-11 F1 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. F1 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 17:45 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $38.09 | $0.00 |
DisclosureSEC source: 0001179110-20-007753 · edgar.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Barlow's continued service to the Company. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 16:18 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $15.71 | $0.00 |
DisclosureSEC source: 0001179110-19-012740 · edgar.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-12-11 F1 · shares: Represents options granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan. F2 · derivative.exercise_date: The stock option will vest and become exercisable with respect to 16,667 shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent two years. All vesting is subject to Dr. Barlow's continued service to the Company through the applicable vesting date. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:33 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 3,144 | $3.18 | $9,997.92 |
DisclosureSEC source: 0001387131-19-006151 · ownership.xml · nonDerivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.17 to 3.18, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 23:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001387131-19-004583 · barlow-form4_062019.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-06-20 Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001387131-18-003025 · barlow-form4_070218.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-07-02 Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 21:20 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001387131-18-001647 · barlow-form4_041718.xml · derivative · entry 1 Barlow Jane F · CIK 0001736026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-04-17 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.